A Phase II Study of ZD 1839 (NSC 715055) [gefitinib] for Patients With First Relapse Glioblastoma Multiforme

Trial Profile

A Phase II Study of ZD 1839 (NSC 715055) [gefitinib] for Patients With First Relapse Glioblastoma Multiforme

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Jun 2013

At a glance

  • Drugs Gefitinib (Primary)
  • Indications Glioblastoma
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 20 Oct 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 20 Oct 2009 Actual end date (Apr 2005) added as reported by ClinicalTrials.gov.
    • 24 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top